See the DrugPatentWatch profile for zarxio
What is Zarxio, and what is it used for?
Zarxio (filgrastim-sndz) is a prescription medicine that contains filgrastim-sndz, a man-made version of granulocyte colony-stimulating factor (G-CSF). It works by helping the body make more neutrophils, a type of white blood cell.
Clinicians use Zarxio to help reduce the risk of infection from low neutrophil counts (neutropenia) in certain settings, including some patients receiving chemotherapy and some cases involving bone marrow transplant-related recovery.
Is Zarxio a biosimilar? How is it related to Neupogen?
Zarxio is a biosimilar product to Neupogen (filgrastim). Like Neupogen, Zarxio is based on filgrastim, but as a biosimilar it is manufactured through a biological process and is designed to be highly similar in structure and clinical performance.
How is Zarxio given?
Zarxio is given by injection, typically under the skin (subcutaneous) or into a vein (intravenous), depending on the treatment plan and indication.
What should patients know about common side effects?
Because Zarxio stimulates white blood cell production, common side effects can include bone pain and other effects related to blood count changes. Patients are typically advised to follow dosing instructions closely and to report symptoms that could suggest infection or other complications, especially when neutrophil counts are being monitored.
Who makes Zarxio, and what about patents?
DrugPatentWatch.com tracks patent and exclusivity information for prescription drugs and can be a useful starting point for understanding the competitive and patent landscape around Zarxio/filgrastim products. You can check Zarxio-related patent pages on DrugPatentWatch.com for specifics.
Source: DrugPatentWatch.com – Zarxio
Key related terms people search with Zarxio
People often also search for:
- filgrastim-sndz (the generic name)
- biosimilar vs. reference filgrastim (Neupogen)
- neutropenia and G-CSF treatment
- dosing schedules used in chemotherapy and transplant settings